Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein

16 Oct 2024

Abstract excerpt

Lipid nanoparticle (LNP) delivery of clustered regularly interspaced short palindromic repeat (CRISPR) ribonucleoproteins (RNPs) could enable high-efficiency, low-toxicity and scalable in vivo genome editing if efficacious RNP-LNP complexes can be reliably produced. Here we engineer a thermostable Cas9 from Geobacillus stearothermophilus (GeoCas9) to generate iGeoCas9 variants capable of >100× more genome editing...

Topics

Join the communities discussing this publication.

CRISPR and Genetic Engineering
Mosquito-borne diseases and control
RNA regulation and disease

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39415058
DOI: 10.1038/s41587-024-02437-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoproteinPMID 39415058Read ↗

Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsSemantic proximity Read ↗

Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticlesSemantic proximity Read ↗

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.Semantic proximity Read ↗

A thermostable Cas9 with increased lifetime in human plasmaSemantic proximity Read ↗

Precise transcript targeting by CRISPR-Csm complexesSemantic proximity Read ↗

Viral delivery of compact CRISPR-Cas12f for <i>in vivo</i> gene editing applicationsSemantic proximity Read ↗

Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cellsSemantic proximity Read ↗

High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogeneticsSemantic proximity Read ↗

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site-Specific Integration of CFTR and Mutation-Agnostic Disease RescueSemantic proximity Read ↗

A TLS11a-decorated ionizable lipid nanoparticle platform and a multilevel-validated CRISPR LDLR-knockout HepG2 model for hepatocyte-preferential mRNA deliverySemantic proximity Read ↗

A lipid nanoparticle platform for high yield CRISPR-targeted homology directed repair enables fully non-viral CAR T cell generationSemantic proximity Read ↗

Non-viral gene editing <i>in utero</i> with lipid nanoparticles complexed to mRNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.